[68Ga]Ga-OncoACP3

DRUG2 trials

Sponsors

Philogen S.p.A.

Conditions

PSA Level Greater Than 0.2Prostate CancerProstate Cancer Metastatic Disease

Phase 1

A Study to Evaluate the Safety and Dosimetry of 68Ga-OncoACP3 in Patients With Prostate Cancer

CompletedNCT06840535

Philogen S.p.A.Prostate Cancer, Prostate Cancer Metastatic Disease, PSA Level Greater Than 0.2

Start: 2025-04-08End: 2025-10-03Updated: 2026-01-06

A Phase I Study to Evaluate the Safety and Dosimetry of Imaging With 68Ga-OncoACP3 in Prostate Cancer

RecruitingNCT07600554

Philogen S.p.A.Prostate Cancer

Start: 2026-05-27End: 2027-12-01Target: 20Updated: 2026-06-10

Related Papers

Diagnostic performance, safety, and biodistribution of [ <sup>68</sup> Ga]Ga-OncoACP3 for PET imaging in prostate cancer: A phase I clinical trial.

Journal of Clinical Oncology2026-05-27